UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
July 2, 2013
Date of Report (Date of earliest event reported)
|
Chimerix, Inc. | ||
| (Exact name of registrant as specified in its charter) | ||
|
Delaware |
001-35867 |
33-0903395 |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer Identification No.) |
| of incorporation) | ||
|
2505 Meridian Parkway, Suite 340 Durham, NC |
| |
| (Address of principal executive offices) | (Zip Code) | |
| Registrant’s telephone number, including area code: (919) 806-1074 | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01 | Regulation FD Disclosure. |
On July 2, 2013, we announced that M. Michelle Berrey, MD, MPH, Chimerix’s Chief Medical Officer, will provide an update on the progress of Chimerix’s CMX001 development program at the 8th Annual JMP Securities Healthcare Conference. Dr. Berrey is scheduled to present at 11:30 am ET on Wednesday, July 10, 2013, in New York City, in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. | Description | |
| 99.1 | Press Release of Chimerix, Inc. dated July 2, 2013. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Chimerix, Inc. | |||||
| Dated: July 2, 2013 | |||||
| By: | /s/ Timothy W. Trost | ||||
| Timothy W. Trost | |||||
| Senior Vice President, Chief Financial Officer and Corporate Secretary | |||||
INDEX TO EXHIBITS
| Exhibit No. | Description | |
| 99.1 | Press Release of Chimerix, Inc. dated July 2, 2013. |
Exhibit 99.1
Chimerix to Present at JMP Securities
Healthcare Conference
DURHAM, NC, July 2, 2013 – Chimerix, Inc. (NASDAQ: CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today that M. Michelle Berrey, MD, MPH, Chimerix’s Chief Medical Officer, will provide an update on the progress of Chimerix’s CMX001 development program at the 8th Annual JMP Securities Healthcare Conference. Dr. Berrey is scheduled to present at 11:30 am ET on Wednesday, July 10, 2013, in New York City.
A live audio webcast of the presentation will be available at http://wsw.com/webcast/jmp21/CMRX or on the Investor Relations section of Chimerix’s website at http://ir.chimerix.com/events.cfm, where it will be archived for 90 days.
About Chimerix
Chimerix, a biopharmaceutical company based in Durham, NC, is committed to the discovery, development and commercialization of novel, oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need. Chimerix's proprietary lipid technology has given rise to two clinical-stage nucleotide analog lipid-conjugates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety in convenient, orally administered dosing regimens. CMX001 has shown broad-spectrum activity against double-stranded DNA viruses, including herpesviruses, adenoviruses and polyomaviruses. Chimerix anticipates beginning the Phase 3 SUPPRESS trial in the third quarter of 2013 for the prevention of cytomegalovirus infection in hematopoietic stem cell transplant recipients. Chimerix's second product candidate, CMX157, an oral nucleotide analog for the treatment of HIV infection, was licensed to Merck in July 2012.
# # #
CHIMERIX CONTACTS:
Rebecca Heath, 919.972.7124
Elizabeth Kelly, 919.972.7109
MEDIA CONTACT:
Tony Plohoros
908.940.0135
tplohoros@6degreespr.com
INVESTOR CONTACT:
Lilian Stern
212.362.1200
lilian@sternir.com